cholestyramine

(redirected from Questran)
Also found in: Medical.
Related to Questran: Questran Light

cho·le·styr·a·mine

 (kō′lĭ-stîr′ə-mēn′, kō-lĕs′tə-răm′ēn)
n.
A drug that binds to intestinal bile acids and promotes their excretion, used to lower serum cholesterol levels and to treat itching associated with partial biliary obstruction.

cholestyramine

(ˌkɒlɪˈstaɪərəˌmiːn)
n
(Pharmacology) a drug that reduces and prevents re-absorption of bile in the body
Translations

cholestyramine

n colestiramina
References in periodicals archive ?
The BAS include colesevelam (Welchol, Daiichi Sankyo Inc, Tokyo, Japan), colestipol (Colestid, Pfizer Inc, New York, New York), and cholestyramine (LoCholest, Warner Chilcott Inc, Rockaway, New Jersey; Prevalite, Upsher-Smith Laboratories, Maple Grove, Minnesota; and Questran, Par Pharmaceutical, Woodcliff Lake, New Jersey).
Pfizer's blockbuster cholesterol treatment, Lipitor, has become the world's best-selling drug, and by 2009, cholesterol-lowering medications, including Crestor, Questran and Lescol, were generating sales of more than $25 billion.
The doctor gave Tom three different scripts for medications (Creon Forte, Questran and Ornidazole treatment), with instructions to try one at a time to see if any would make a difference to his bowels.
These include Dilantin (used for seizures), steroid medications such as prednisone used to reduce inflammation or treat asthma, and Questran (cholestyramine), a cholesterol-lowering medication.
xx Advicor, Altocor, Altoprev, Caduet, cholestyramine, cholestyramine light, Colestid, Crestor, fenofibrate, gemfibrozil, Lescol, Lescol XL, Lipitor, Locholest, Lofibra, Lopid, lovastatin, Mevacor, Niaspan, Pravachol, Pravigard PAC, Prevalite, Questran, Questran Light, Tricor, Welchol, Zetia, Zocor Depression 296.
Par will offer cholestyramine in oral suspension, 4-gram resin/9-gram powder (generic Questran powder) and 4-gram resin/5-gram powder (generic Questran light powder).
The Flagyl and Questran were stopped and Ciprofloxacin 500 mg p.
An OTC switch for Questran, also a Bristol-Myers Squibb product, has been reviewed twice at hearings over the past 5 years, but the idea has been rejected twice.